Revolutionizing the Treatment of Aortic Arch Aneurysms
Bringing RIBS to the World
Bringing New Hope to Patients with Life-Threatening Diseases
Aortic arch aneurysms have long been considered among the most challenging conditions to treat with endovascular therapy.
RIBS (Retrograde In Situ Branched Stent Grafting) is changing that paradigm.
Through its unique approach to preserving blood flow to the supra-aortic branches, RIBS expands the reach of minimally invasive treatment to patients who previously had few or no endovascular treatment options.
RIBS Is Redefining the Limits of Treatment.
Many patients with aortic aneurysms continue to face life-threatening risks because their treatment options remain limited. Among them, aortic arch aneurysms have been particularly challenging, as their complex anatomy has significantly restricted the use of minimally invasive endovascular treatment.
At RIBS, we are committed to fundamentally changing this reality through the development of the RIBS Stent Graft System. Designed to enable endovascular treatment in the aortic arch—an area that has long been difficult to treat with conventional technologies—our system has the potential to expand treatment options for patients with complex aortic disease.
Through this innovative approach, we aim to establish the next standard in aortic care.
Safer, less invasive treatment.
Reduced procedural risk and faster patient recovery.
Better quality of life for every patient.
Through the development of the RIBS Stent Graft System, we are committed to bringing new hope to patients who previously had limited treatment options and to advancing the future of cardiovascular care.
